Latest news with #NASH
Economic Times
11 hours ago
- Health
- Economic Times
India's silent epidemic: 6 foods to include in your diet if you have fatty liver
India faces a growing health crisis as liver diseases, including fatty liver disease and hepatitis, surge among younger adults in their twenties and thirties. This alarming trend highlights the need for proactive health measures. Incorporating liver-friendly foods like coffee, garlic, fatty fish, grapes, nuts, and berries into daily diets can significantly aid in preserving liver function and preventing disease progression. Have fatty liver? Here are some food items that are good for your liver. Tired of too many ads? Remove Ads Understanding NAFLD: A Growing Liver Disorder Nutritional Allies in Combating Fatty Liver Tired of too many ads? Remove Ads Coffee: A Morning Shield for the Liver Garlic: The Pungent Protector Fatty Fish: Omega-3 Powerhouses Grapes: Nature's Liver Tonic Nuts: Crunchy Guards Against Inflammation Berries: Polyphenol-Rich Superfoods Conclusion: Liver Care Must Begin Early While India is rapidly advancing toward becoming the global hub for diabetes, another equally alarming health concern is emerging in its shadow. A dramatic increase in liver-related conditions such as fatty liver disease, hepatitis, and cirrhosis is now surfacing, and worryingly, the trend is no longer restricted to the elderly. According to insights shared by the Financial Express, individuals in their twenties and thirties are now frequently being diagnosed with significant liver dysfunctions, signaling a quiet but deadly shift in the nation's public health landscape. Non-Alcoholic Fatty Liver Disease (NAFLD) refers to a chronic condition where fat accumulates in the liver in individuals who drink little to no alcohol. It commonly affects people struggling with obesity or those who have type 2 diabetes. As explained in a report by Healthline, NAFLD is categorized into two main types:Simple Fatty Liver (NAFL): In this form, excess fat builds up in the liver without causing inflammation. However, the organ may enlarge, leading to discomfort or mild Steatohepatitis (NASH): This more severe form involves liver inflammation and damage, which, if not managed, can progress to cirrhosis or even liver coffee consumption might offer more than just a caffeine kick. A 2021 review mentioned by Healthline found that people who regularly drink coffee have a reduced risk of developing NAFLD. It also appears to minimize the progression of liver scarring in diagnosed patients and lowers abnormal liver enzyme has shown promise in improving liver health. Medical News Today cited a 2020 clinical trial which demonstrated that taking 800 mg of garlic powder over 15 weeks reduced fat accumulation in the liver and improved metabolic health in NAFLD patients. Furthermore, observational studies in China have hinted that raw garlic consumption may lower the chances of liver cancer. However, while garlic supplements may reduce AST liver enzyme levels, more evidence is needed to confirm all rich in omega-3 fatty acids—such as sardines, tuna, salmon, and trout—offer significant liver support. According to Healthline, these fats help lower liver fat content, elevate protective HDL cholesterol, and bring down triglyceride levels. This nutritional intervention is particularly useful for individuals living with especially the seeded variety, are rich in beneficial compounds located in their skin and seeds. Studies mentioned in Medical News Today suggest that these components help reduce liver swelling, inflammation, and fat storage in animal models. Adding whole grapes to the diet or taking grape seed extract may provide potent antioxidant are rich in unsaturated fats, antioxidants, and vitamin E—all essential nutrients for liver protection. Regular consumption may help decrease inflammation and oxidative stress, potentially staving off the onset of NAFLD, as per studies referenced in berries like blueberries, cranberries, and raspberries contain polyphenols that have shown liver-protective effects in research on animals. A 2023 study revealed that these compounds helped reduce liver injury in rats, while an earlier 2019 investigation found a link between blueberry intake and reduced liver liver diseases silently infiltrate younger populations in India, proactive health measures and dietary awareness are more crucial than ever. By integrating scientifically backed food choices into daily routines, people can take significant steps toward preserving liver function and preventing the progression of NAFLD and related complications.
Time of India
12 hours ago
- Health
- Time of India
India's silent epidemic: 6 foods to include in your diet if you have fatty liver
Understanding NAFLD: A Growing Liver Disorder Nutritional Allies in Combating Fatty Liver Coffee: A Morning Shield for the Liver Garlic: The Pungent Protector Fatty Fish: Omega-3 Powerhouses Grapes: Nature's Liver Tonic Nuts: Crunchy Guards Against Inflammation Berries: Polyphenol-Rich Superfoods Conclusion: Liver Care Must Begin Early While India is rapidly advancing toward becoming the global hub for diabetes, another equally alarming health concern is emerging in its shadow. A dramatic increase in liver-related conditions such as fatty liver disease, hepatitis, and cirrhosis is now surfacing, and worryingly, the trend is no longer restricted to the elderly. According to insights shared by the Financial Express, individuals in their twenties and thirties are now frequently being diagnosed with significant liver dysfunctions, signaling a quiet but deadly shift in the nation's public health landscape. Non-Alcoholic Fatty Liver Disease (NAFLD) refers to a chronic condition where fat accumulates in the liver in individuals who drink little to no alcohol. It commonly affects people struggling with obesity or those who have type 2 diabetes. As explained in a report by Healthline, NAFLD is categorized into two main types:Simple Fatty Liver (NAFL): In this form, excess fat builds up in the liver without causing inflammation. However, the organ may enlarge, leading to discomfort or mild Steatohepatitis (NASH): This more severe form involves liver inflammation and damage, which, if not managed, can progress to cirrhosis or even liver coffee consumption might offer more than just a caffeine kick. A 2021 review mentioned by Healthline found that people who regularly drink coffee have a reduced risk of developing NAFLD. It also appears to minimize the progression of liver scarring in diagnosed patients and lowers abnormal liver enzyme has shown promise in improving liver health. Medical News Today cited a 2020 clinical trial which demonstrated that taking 800 mg of garlic powder over 15 weeks reduced fat accumulation in the liver and improved metabolic health in NAFLD patients. Furthermore, observational studies in China have hinted that raw garlic consumption may lower the chances of liver cancer. However, while garlic supplements may reduce AST liver enzyme levels, more evidence is needed to confirm all rich in omega-3 fatty acids—such as sardines, tuna, salmon, and trout—offer significant liver support. According to Healthline, these fats help lower liver fat content, elevate protective HDL cholesterol, and bring down triglyceride levels. This nutritional intervention is particularly useful for individuals living with especially the seeded variety, are rich in beneficial compounds located in their skin and seeds. Studies mentioned in Medical News Today suggest that these components help reduce liver swelling, inflammation, and fat storage in animal models. Adding whole grapes to the diet or taking grape seed extract may provide potent antioxidant are rich in unsaturated fats, antioxidants, and vitamin E—all essential nutrients for liver protection. Regular consumption may help decrease inflammation and oxidative stress, potentially staving off the onset of NAFLD, as per studies referenced in berries like blueberries, cranberries, and raspberries contain polyphenols that have shown liver-protective effects in research on animals. A 2023 study revealed that these compounds helped reduce liver injury in rats, while an earlier 2019 investigation found a link between blueberry intake and reduced liver liver diseases silently infiltrate younger populations in India, proactive health measures and dietary awareness are more crucial than ever. By integrating scientifically backed food choices into daily routines, people can take significant steps toward preserving liver function and preventing the progression of NAFLD and related complications.
Reuters
15 hours ago
- Health
- Reuters
EU medicines regulator grants conditional authorisation for Madrigal's liver disease drug
June 20 (Reuters) - The European Union's medicines regulator on Friday granted a conditional authorisation for Madrigal Pharmaceuticals' (MDGL.O), opens new tab drug for a type of fatty liver disease, paving the way to make it the first treatment available for the condition in the region. The drug, sold as Rezdiffra, was first approved in the United States in March last year. The disease known as non-alcoholic steatohepatitis (NASH), or more recently renamed as metabolic dysfunction-associated steatohepatitis (MASH), causes excess build up of fat in the liver, resulting in inflammation and fibrosis, or scarring, of the organ.
Time of India
6 days ago
- Health
- Time of India
Fatty liver: Symptoms and warning signs seen during the night
Fatty liver disease, particularly Non-Alcoholic Fatty Liver Disease (NAFLD), is a growing health concern, affecting an estimated 30.2% of the world's population. Prevalence varies by region, with rates above 40% in the Americas and Southeast Asia. What is Non-Alcoholic Fatty Liver Disease (NAFLD)? Non-alcoholic fatty liver disease (NAFLD) is a condition where excess fat builds up in the liver, not caused by heavy alcohol consumption. It's often linked to obesity, type 2 diabetes, and metabolic syndrome. NAFLD encompasses a spectrum of conditions, from simple fat buildup (NAFL) to more serious inflammation and scarring (NASH). Often termed the "silent epidemic," NAFLD can progress to more severe conditions like cirrhosis if left unchecked. While many symptoms manifest during the day, certain warning signs become more pronounced at night. Recognizing these nocturnal symptoms is crucial for early detection and management. Excessive night sweats One of the alarming nighttime symptoms of fatty liver disease is excessive sweating during sleep. Individuals may wake up drenched in sweat, even in a cool room. This occurs because the liver's impaired function affects the body's ability to regulate temperature effectively. Persistent fatigue and weakness Fatigue is a hallmark of fatty liver disease. However, when the liver's detoxification processes are compromised, individuals may experience overwhelming tiredness during the night. This isn't just typical tiredness; it's an overpowering fatigue that can interfere with daily life. Sleep disturbances and insomnia Individuals with fatty liver disease often report difficulty falling or staying asleep. The discomfort from liver inflammation or the body's struggle to process toxins can lead to restless nights. Moreover, the liver's reduced ability to store and release glycogen can cause blood sugar imbalances, further disrupting sleep patterns. Abdominal discomfort intensifying at night A common symptom of fatty liver disease is discomfort in the upper right abdomen. This sensation can worsen at night, making it hard to get a good night's sleep. People may feel a sense of fullness or pressure, which can be quite concerning. Loss of appetite during evening meals A decrease in appetite, particularly at night, may signify fatty liver disease. Individuals may find they have less interest in food, especially during dinner, which could eventually lead to weight loss and nutritional problems. Increased brain fog and mental fatigue As fatty liver disease progresses, the accumulation of toxins in the bloodstream can affect brain function. This may lead to symptoms like confusion, poor memory, or trouble focusing, commonly referred to as "brain fog." These cognitive disturbances can be more noticeable during the evening or night when the body is at rest. Swelling in the legs and feet While swelling can occur at any time, it may become more noticeable at night. Fluid retention due to liver dysfunction can lead to swelling in the legs and feet, causing discomfort and affecting sleep quality. Itchy skin Fatty liver disease can cause itchy skin, especially if liver damage affects bile flow. When bile salts build up under the skin, it can cause irritation and itching, even if there is no visible rash. Unexplained weight loss Unexplained weight loss can be an early indicator of fatty liver disease. The liver's involvement in various metabolic processes, including the regulation of body weight, can be disrupted, leading to unintended weight loss. Yellowing of the skin or eyes (Jaundice) In more advanced stages of fatty liver disease, jaundice can develop. This condition causes the skin and the whites of the eyes to turn yellow due to elevated levels of bilirubin, a waste product from red blood cells. Jaundice is a serious sign and should be checked by a doctor immediately. While adopting a healthy lifestyle – which consists of a balanced diet, regular exercise, checking alcohol consumption and smoking, and having adequate sleep – can significantly elevate liver health, if you experience any of the above symptoms, especially during the night, it's essential to consult a healthcare professional. Early detection through blood tests and imaging can help manage and potentially reverse the effects of fatty liver disease. Know the signs of liver problems in children One step to a healthier you—join Times Health+ Yoga and feel the change
Globe and Mail
12-06-2025
- Business
- Globe and Mail
NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies
DelveInsight's, 'Nonalcoholic Steatohepatitis Pipeline Insight, 2025' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight's comprehensive report today! @ NASH Pipeline Outlook Key Takeaways from the NASH Pipeline Report In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period. In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH). DelveInsight's NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment. The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs NASH Emerging Drugs Profile Lanifibranor: Inventiva Pharma Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH. MSDC-0602K: Cirius Therapeutics MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH. TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH. HTD 1801: HighTide Biopharma The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The NASH Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment. NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight's detailed report now! @ New NASH Drugs NASH Companies Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical NASH Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight's expert analysis @ NASH Market Drivers and Barriers Scope of the NASH Pipeline Report Coverage- Global NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Nonalcoholic Steatohepatitis: Overview Pipeline Therapeutics Therapeutic Assessment Nonalcoholic Steatohepatitis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Lanifibranor: Inventiva Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) TERN-501: Terns Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) LY3849891: Eli Lilly and Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name : Company name Drug profiles in the detailed report….. Inactive Products Nonalcoholic Steatohepatitis Key Companies Nonalcoholic Steatohepatitis Key Products Nonalcoholic Steatohepatitis- Unmet Needs Nonalcoholic Steatohepatitis- Market Drivers and Barriers Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion Nonalcoholic Steatohepatitis Analyst Views Nonalcoholic Steatohepatitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
